Psychological risk factors are involved in the pathogenesis of cardiovascular diseases (CVD) and
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There is considerable evidence that psychosocial stress (PS) plays an important role in the pathogenesis and progression of cardiovascular disease (CVD). [1] [2] [3] Despite the widespread belief by lay people that PS worsens many medical conditions, including CVD, we believe that the importance of stress has been unrecognized or under appreciated by the medical community, especially among practioners in CVD. [1] [2] [3] [4] PS is one of the most frequent complaints from patients, and PS adversely impacts numerous important medical conditions, including most chronic diseases (cancer, diabetes mellitus, arthritis, lung disease, human immunodeficiency virus), as well as CVD. [1] [2] [3] [4] [5] [6] Certainly, the link between PS and CVD is becoming increasingly better established. [1] [2] [3] [4] [5] [6] Cardiac rehabilitation and exercise training ( ET ;CRET) programs are an integral part of providing optimal medical therapy to patients with established coronary heart disease (CHD). [7] [8] [9] Substantial data from CRET programs have demonstrated dramatic improvements in exercise capacity or cardiorespiratory fitness (CRF), various CHD risk factors (lipids, glucose, blood pressure, inflammation), as well as measures of PS and quality of life . 7, 8 Although no single study has demonstrated major reductions in morbidity and mortality, with few exceptions, most major meta-analyses over the past 3 decades have demonstrated reductions in morbidity and mortality. 9, 10 In this select review of the area, we discuss the role of PS to impact CVD, the high prevalence of PS in patients with CVD, especially CHD, and the impact of CRET to reduce PS and PSassociated mortality risk. Finally, we review recent evidence on the potential importance of M A N U S C R I P T
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Does Psychological Stress Increase Cardiovascular Disease Risk?
We believe thatthe topic of PS has been under-recognized by clinicians in most medical specialties, especially specialties in CVD. [1] [2] [3] [4] [5] [6] However, the lay public has been extremely interested in this topic in general and on the impact of PS on CVD. 4 Over the past 2 decades, the link between PS and CVD has become increasingly well-established. [1] [2] [3] [4] [5] [6] Epidemiological data and prospective studies have explored the complex relationship between PS and CVD. [1] [2] [3] [4] [5] [6] When PS has been assessed by validated screening instruments, the clinical impact of PS has been comparable with many of the major CHD risk factors, including smoking, hypertension and low physical activity (PA). [1] [2] [3] [4] [5] [6] Although most of the literature in PS has focused on depression and CVD, there is substantial evidence that other components of PS, including anxiety, hostility, isolation, strong adverse emotions, time urgency, and total PS, have significant impact on acute and chronic aspects of CVD. 1 Certainly there is substantial evidence M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
6 nonpharmacologic and drug treatment regimens, poor health habits, as well as substance abuse. 5, 11 Arguably the most important epidemiologic data on the critical role of PS and CHD comes from the INTERHEART study, 12 which evaluated major CHD risk factors and PS among a diverse group of 11,119 myocardial infarction patients and 13,648 age-and gender-matched control subjects from 52 countries and 262 centers. This landmark study demonstrated that among 9 major modifiable CHD risk factors, PS was third behind only lipids and smoking in importance, and PS accounted for close to 1/3 the total attributable risk for acute infarction. In addition,
epidemiological and laboratory studies have demonstrated that mental stress may provoke myocardial ischemia in the laboratory and during daily life, and mental stress-induced myocardial ischemia is associated with worse prognosis, over and above exercise testing. 5, 13, 14 Potential reasons for these findings are numerous, but particularly important is that the autonomic nervous system (ANS) probably plays a significant role in mediating the effects of PS and CVD. 11, 15, 16 Chronic imbalance of the ANS, with a shift toward higher sympathetic as opposed to parasympathetic/vagal tone, may worsen CVD prognosis. In fact, over activation of the sympathetic nervous system may worsen endothelial function and coronary artery tone and predispose to various rhythm disorders, platelet activation and thrombosis, as well as elevated blood pressure and left ventricular hypertrophy, whereas parasympathetic activation or withdrawal has benefiscial and adverse effects on CVD,respectively Many forms of PS will alter the balance between sympathetic to vagal tone, which clinically may be manifest as reduced heart rate variability , increased resting heart rate, blunted exercise heart rate and delayed heart M A N U S C R I P T
7 rate recovery following exercise, all evidence of ANS dysfunction that may increase the risk of CVD events.
PS and CVD
Although there are many aspects of PS which may worsen CVD, our research has largely focused on anxiety, hostility (or un-expressed anger) and depression in CHD.
Anxiety and CVD. Although probably less established than is the relationship of depression with CVD, a causal relationship has been suggested between anxiety and CVD. 1, 17, 18 Several studies have suggested that anxiety may be an independent predictor of CHD morbidity and mortality. 1, 5, 19, 20 Elevated anxiety symptoms have been shown to be associated with a 2-fold increased risk of mortality in patients who have had coronary artery bypass graft surgery 21, 22 and in outpatients with CHD. 23, 24 Frasure-Smith and colleagues 25 reported that CHD patients with generalized anxiety disorder assessed two months following hospital discharge showed a 2.3-fold increased risk of adverse CVD events, and Strik et al. 26 reported a 2.8-fold increased risk of adverse events in acute post-infarct patients in which anxiety was measured one month following hospital discharge. Similarly, a 2-fold increased risk of adverse events was observed in stable CHD patients 23 and in patients with elevated anxiety during annual clinic visits. 27 Elevated anxiety symptoms in the coronary care unit are associated with increased mortality within the first years post-acute infarction. 28 . Anxiety appears to be prevalent among patients with CVD, perhaps more so in the younger CHD patients ( Figure 2 ). have been estimated to be as high as 25%, with point prevalence rates estimated at up to 45% for patients with minor depression or elevated depressive symptoms. 38 Depression also has been associated with more than a 2-fold increased risk for patients undergoing bypass surgery. 39 In one meta-analysis of 20 prospective studies of patients with CHD, depressive symptoms were associated with an odds ratio of 2.24 for mortality. 40 The American Heart Association recently recognized depression as a risk factor for patients with CHD, and encouraged routine assessment of depressive symptoms. 41 Additionally, Grace and colleagues 42 demonstrate that depression at the time of CVD hospitalization not only impacted quality of life but also subsequent mortality.
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A sense of hopelessness, particularly, seems to be strongly correlated with adverse CVD
outcomes. Major studies have demonstrated a very high prevalence of depression among CHD
patients, probably moreso in women, 43 and slightly moreso in younger as opposed to older CHD patients, 18 although older patients have much higher prevalence of depression than anxiety or hostility ( Figure 2 ). Patients with diabetes seem to particularly have a high prevalence of depression.
44,45
Impact of CRET on PS
We and others have demonstrated the powerful effects of CRET and improvements in CRF on PS and PS-induced mortality.
Role of CRET in Anxiety. Patients with CHD, especially younger patients, have a very high prevalence of anxiety ( Figure 2 ). 18 Following formal CRET, the prevalence of anxiety (Kellner Anxiety Score > 7) and high anxiety (Kellner Anxiety Score > 10) fell by 56% and 69%, respectively in one study, 17 and then in another study fell by 61% in younger patients and by 32% in older CHD patients (Table 1) . 18 A meta-analysis mostly from CVD cohorts also demonstrated that ET significantly reduced anxiety symptoms. 46 Role of CRET in Hostility. Over fifteen years ago, we demonstrated that following CRET, hostility, which is often defined as unexpressed anger and defined in our study as Kellner Hostility Score > 7, fell from 28% at baseline to 15% in young patients and from 8% to only 4% in those older than 65 years. 47 In a more recent study ( Figure 2 , Table 1 ), 18 we demonstrated greater than 50% reductions in the prevalence of hostility in both younger and older CHD patients.
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Impact of CRET on Depressive Symptoms. Probably the most powerful evidence of the role of CRET in secondary CHD prevention is in patients with depression. Although depressive symptoms seem to be prevalent in CHD patients regardless of age, the prevalence of depressive symptoms ( Kellner Depression Score > 6) seems to be especially high in CHD patients with diabetes 44, 45 and in women. 43 However, following formal CRET programs, the prevalence of depression generally is reduced by over 50%.
18
Especially noteworthy is the impact of CRET to reduce not only depressive symptoms but depression-related increased mortality. In a study of 522 consecutive CHD patients enrolled in CRET and in 179 CHD patients who did not complete CRET, we assessed the impact of depressive symptoms on subsequent survival. 48 Following CRET, the prevalence of depressive symptoms fell from 17% to only 6% (minus 63%; p<0.001). Moreover, depressive symptoms in CHD patients following CRET had a 4-fold higher mortality than did non-depressed patients, and in those with baseline depressive symptoms who completed CRET, mortality was 73% lower compared with depressed patients who did not participate in formal CRET programs (8% versus 30%; p=0.005). Since CRET involves more than just ET intervention, as discussed in detail in this Symposium, we assessed changes in CRF and subsequent risk of depression and mortality.
Using cardiopulmonary gas exchange to precisely assess CRF before and after CRET, we demonstrated that those who did not improve their peak oxygen consumption (peak VO 2 )
continued to have a high prevalence of depressive symptoms and high mortality risk during follow-up ( Figure 3 ). 48 However, those who either had small improvements or more marked improvements in peak VO 2 both had striking reductions in the prevalence of depressive M A N U S C R I P T
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11 symptoms and depression-related increased mortality risk. In a randomized control trial of 101 CHD patients, ET and sertraline therapy both resulted in greater reductions in depressive symptoms and improvements in heart rate variability compared with placebo, although there appeared to be a trend to greater benefit with ET than with sertraline (p=0.09). 49 The HF :ACTION was a large randomized trial of ET versus usual care in 2,322 patients with systolic heart failure (HF ) and demonstrated significant benefits of ET over usual care in both reducing depression symptoms and clinical events, despite only inducing a mean improvement in peak VO 2 of 4 %. 50 We also assessed the impact of CRET on depression and survival in CHD patients with systolic HF. 51 Similar to non-HF patients with CHD, depression fell from 22% to 13% following CRET (-40%; p<0.001). Those who were initially depressed and who remained depressed following CRET had a 4-fold higher mortality than did HF patients whose depression resolved with CRET (43% versus 11%; p=0.005). Additionally, HF patients who completed CRET had considerably lower mortality than did HF patients who did not complete CRET (18% versus 44%; -59%; p<0.005). As with non-HF patients, the survival benefits following CRET are mostly noted in depressed HF patients who significantly improved peak VO 2 following CRET ( Figure 4 ). 51 Benefits of CRET on Total PS. We previously assessed 500 consecutive CHD patients and demonstrated that improvements following CRET were similar or even greater in those with high as opposed to low PS ( based on combined Kellner scores for depression, anxiety, hostility , and somatization.) 52 In another study, we combined Kellner scores for anxiety, hostility and depression for a total PS score, which predicted mortality in 522 consecutive CHD patients.
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12 fact, almost all of the mortality during follow-up was noted in those with high PS who did not improve CRF (defined as <10% improvement in peak VO 2 following CRET). On the other hand, patients with low PS at baseline and those with high PS who significantly improved their peak VO 2 by at least 10% had low 3-year mortality ( Figure 5 ). 53 Finally, in a study of 538 who completed CRET, we assessed whether other PS contributed to mortality risk. 54 Following CRET, we compared mortality in 502 non-depressed patients with mortality in 14 patients with depressive symptoms alone and 22 patients with depressive symptoms combined with anxiety and/or hostility symptoms. Although there was a trend of higher mortality in the comorbid depression group compared with depression alone (23% versus 14%; p=NS), the overall impact was largely driven by depressive symptoms (19% mortality versus 3% in non-depressed patients; p<0.001). This study was limited, however, by the fairly low prevalence of PS following formal CRET.
Addition of Stress Management Training to Routine CRET
In a series of studies of patients with mental-stress induced myocardial ischemia, Blumenthal and colleagues reported that patients randomized to either SMT or ET had better clinical outcomes compared to non-randomized usual care controls. 55 Moreover, SMT and ET produced complementary benefits: SMT reduced mental stress-induced ischemia while ET reduced exercise-induced ischemia. In a subsequent, fully randomized trial, SMT and ET each produced comparable improvements in psychological functioning as well as greater improvements in biomarkers of CVD risk compared to usual care controls. 56 While these studies compared ET to Interestingly not all studies have found SMT to improve clinical outcomes. In a study of 2,328 post-infarction patients randomized to 7 weekly sessions of SMT or usual care and followed for 12 months, Jones and West 58 reported that prevalence rates of anxiety and depression remained high and there were no important group differences following treatment and no differences in major clinical end-points. In 1,376 post-MI patients, Frasure-Smith and colleagues 59 randomized patients to telephone-based SMT versus usual care, and also found no group differences in PS or clinical outcomes during follow-up. The ENRICHD trial 60 
Potential Mechanisms for PS Benefits
The mechanism by which behavioral factors and PS contribute to CVD and CHD is not completely understood but likely multifactorial, including worsening CHD risk factors which contribute to atherosclerosis, adverse effects on the ANS, inflammation, enhanced platelet activation, circulating catecholamines, cortisol, reduced myocardial ischemia, and enhanced coronary vasoreactivity and constriction. 1, 30, 48 Likewise, an improvement in risk factors and PS following CRET is also probably multifaceted. Certainly, the CRET programs are centered around increasing PA and ET to improve CRF, which correlates with most of the improvements and prognosis with CRET therapy in general and for PS. However, CRET also has beneficial effects on certain emotions and improving ANS function, 16 and improves inflammation, 61, 62 metabolic syndrome 63, 64 and blood rheology. 65 Some evidence suggests that ET also has favorable effects on brain plasticity and cognition. 66, 67 In fact, CRET involves more than just ET, and other aspects of the Phase II CRET programs involve education of the patients and their significant others, which may also be important by increasing understanding of the underlying M A N U S C R I P T
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15 disease process and its manifestations, therefore "empowering" patients to modify their own recovery, which is a process called "information involvement," which may also enhance coping mechanisms as well as emotional and social recovery processes. 66, 67 In addition, CRET programs have aspects of "group therapy," that is often used by psychologists and psychiatrists that may promote socialization and bonding with other patients in CRET who are at various stages in their recovery process. 66, 68 Despite the significant improvements in PS following CRET, many patients continue to experience PS following CRET and have high morbidity and mortality. Further therapy directed at PS, including behavior modification, psychotherapy, and/or pharmacologic intervention could be required. 66, 69, 70 The recent data with SMT seems particularly attractive for improving the already substantial improvements noted with CRET.
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Limitations
Several limitations of the studies discussed in this paper should also be noted. Many of the Ochsner studies were not randomized, which raises the possibility of non-specific effects, regression to the mean or selection bias. However, since CRET programs are well established around the world 7-9,71-73 it is difficult to randomize patients to no CRET therapy in which they
would be denied what is now considered the standard of care for patients with CVD. Also, much of the data that we presented comes from a single center ( Ochsner Medical Center in New
Orleans,LA) with a strong clinical and research emphasis on CRET and PS, so other CRET investigators also need to evaluate the impact of CRET and unique CRET delivery systems on psychological risk factors and subsequent prognosis. 
